ARCHIVES

SPORE Eligibility, Cost Issues Clarified In Addendum To RFA

This article is from The Cancer Letter archive.

Vol. 17 No. 41 | October 25, 1991

Download PDF Visit The Full Archive

Related Articles

After the Plenary: Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant

July 11, 2014

Oncologists Tell Congress Community Cancer Practices Are Not Adequately Reimbursed

April 4, 2014

GAO Offers Two Suggestions For Plant Screening

April 4, 1980

Wallen Pleads Guilty To Lesser Charges, To Pay $20,000 to CALGB, FDA

August 31, 1984

NCAB To Consider Fate Of Existing Two Proposed Comp Center At Important Meeting

April 28, 1978

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

November 29, 2013